+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 75Years
All Genders
ID06931990

Exploring Safety, Tolerability, and Efficacy of LT-002-158 Tablets in Chinese Adults with Moderate to Severe Atopic Dermatitis

Led by Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. · Updated on 2026-08-27

24

Participants Needed

1

Research Sites

6 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a Phase IcII clinical trial to study LT-002-158 tablets in Chinese adults with moderate to severe atopic dermatitis. The trial mainly focuses on evaluating the safety, tolerability, and efficacy of the drug. The Phase Ic part is an open-label, randomized study assessing safety and tolerability, while the Phase II part is a randomized, double-blind, placebo-controlled study exploring the drugs effectiveness in this condition. Participants will receive oral doses of LT-002-158 tablets once daily. The study includes different dosage groups to compare effects and includes an extended treatment arm in the Phase II portion. Each participants treatment duration and dose will be managed according to the study design to assess the drugs impact on atopic dermatitis symptoms. During the trial, participants will undergo regular visits to monitor adverse events and drug levels in the blood. Researchers will measure treatment-emergent adverse events up to 42 days, along with pharmacokinetic parameters such as plasma concentration levels. Participants will be expected to complete all planned visits, treatments, and procedures, including daily use of moisturizers and diary record keeping, until the study concludes.

CONDITIONS

Brief Title

A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Subjects With Atopic Dermatitis

Research Team

J

Juan Xu

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here